Circulating tumor cell (CTC) analysis of biomarkers and outcomes in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone

Weimin Li,¹ Takefumi Satoh,² Hiroji Uemura,³ Tsutomu Nishiyama,⁴ Bie Verbst,⁵ Denis Smirnov,¹ Shuji Nagasaki,⁵ Ryo Oyama,⁶ Brad Foulk,¹ Jaymala Patel,¹ Kathy Zelinsky,¹ Deborah S. Ricci,⁷ Kazuhiro Kawaguchi,⁶ Hideyuki Akaza⁶

¹Janssen Research & Development, Spring House, PA; ²Kitasato University School of Medicine, Sagamihara, Japan; ³Yokohama City University Hospital, Yokohama, Japan; ⁴Niigata University Medical and Dental Hospital, Niigata, Japan; ⁵Janssen Research & Development, Beerse, Belgium; ⁶Janssen Pharmaceutical KK, Tokyo, Japan; ⁷Janssen Research & Development, Raritan, NJ; ⁸University of Tokyo, Tokyo, Japan

Background
Biomarkers are essential for predicting efficacy and resistance of abiraterone acetate plus prednisone. We conducted an exploratory analysis of CTC biomarker associations with outcomes in 2 phase 2 trials of Japanese mCRPC patients treated with abiraterone acetate plus prednisone.

Methods
Patients with (n = 47) or without (n = 48) prior docetaxel treatment were included. Select CTC biomarkers were evaluated at baseline and end of treatment (EOT; n = 26 and n = 38 patients with and without prior docetaxel, respectively) using androgen receptor (AR) nuclear protein staining and mRNA expression analyses. Treatment effect and biomarker associations with clinical end points were assessed by Cox proportional hazard models, with number of CTCs as a covariate. Clinical end points included prostate-specific antigen (PSA) response (≥ 50% decline) by 12 weeks (primary), overall survival (OS), PSA progression-free survival (PFS), and radiographic PFS (rPFS).

Results
PSMA expression was higher at EOT versus baseline (69% vs 48%; p = 0.003). ARv1 and ARv7 expression were higher at EOT (40% vs 10% and 48% vs 26%, respectively; p < 0.01). Normalized expression of IFIH1 and CDH1 markers decreased in docetaxel-resistant tumors and was lower at EOT versus baseline and in samples with ≥ 5 CTCs at baseline and EOT. Higher frequency of baseline PSMA was associated with shorter OS, rPFS, and PFS (HR = 4.9, 2.3, and 3.2, respectively; p < 0.05), and positive EOT PSMA was associated with lower PSA response rate (31% in PSMA+ vs 75% in PSMA−; p = 0.01) and shorter PFS (HR = 3.1; p = 0.04). BL ARv7 showed no association with PSA response, OS, PFS, or rPFS (p > 0.05). 44% of patients with baseline ARv7 expression had a PSA response versus 47% without baseline ARv7 expression. Baseline AR full length (AR FL) was associated with PFS (HR = 2.5; p = 0.004), with no evidence of association between EOT AR FL and outcomes. EOT expression of NPY (neuropeptide), UBE2C (proliferation marker), and ACADL (androgen-related dehydrogenase) was associated with worse outcomes.

Conclusions
This study is the first to find an association between higher frequency of baseline or EOT PSMA and resistance to abiraterone acetate plus prednisone. Baseline ARv7 did not show an association with outcomes. These findings require validation in large-scale prospective studies.
**Conflict of Interest:**

W Li and D Ricci have been employed by Janssen Research & Development and have owned stock or held an ownership interest with Johnson & Johnson.

T Satoh has received honoraria from Daiichi Sankyo, AstraZeneca, Janssen Pharmaceuticals, and Astellas Pharma.

H Uemura has received honoraria and research funding from Astellas Pharma, and honoraria from Daiichi Sankyo, AstraZeneca, Janssen Pharmaceuticals, Bayer and Takeda.

T Nishiyama does not have any relevant financial relationships to disclose.

B Verbist, B Foulk, J Patel, and K Zelinsky have been employed by Janssen Research & Development.

S Nagasaki, R Oyama, and K Kawaguchi have been employed by Janssen Pharmaceutical KK.

H Akaza has received honoraria and research funding from Astellas Pharma, Janssen Pharmaceuticals, and Takeda.

**Funding Acknowledgements:** This study was funded by Janssen Research & Development.